Skip to main content
main-content

27.08.2018 | Pancreatic Tumors | Ausgabe 12/2018 Open Access

Annals of Surgical Oncology 12/2018

Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 12/2018
Autoren:
J. V. Groen, B. G. Sibinga Mulder, E. van Eycken, Z. Valerianova, J. M. Borras, L. G. M. van der Geest, G. Capretti, A. Schlesinger-Raab, M. Primic-Zakelj, A. Ryzhov, C. J. H. van de Velde, B. A. Bonsing, E. Bastiaannet, J. S. D. Mieog
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-6705-1) contains supplementary material, which is available to authorized users.

Abstract

Background

The EUropean REgistration of Cancer CAre (EURECCA) consortium aims to investigate differences in treatment and to improve cancer care through Europe. The purpose of this study was to compare neo- and adjuvant chemotherapy (ACT) and outcome after tumor resection for pancreatic adenocarcinoma stage I and II in the EURECCA Pancreas consortium.

Methods

The eight, collaborating national, regional, and single-center partners shared their anonymized dataset. Patients diagnosed in 2012–2013 who underwent tumor resection for pancreatic adenocarcinoma stage I and II were investigated with respect to treatment and survival and compared using uni- and multivariable logistic and Cox regression analyses. All comparisons were performed separately per registry type: national, regional, and single-center registries.

Results

In total, 2052 patients were included. Stage II was present in the majority of patients. The use of neo-ACT was limited in most registries (range 2.8–15.5%) and was only different between Belgium and The Netherlands after adjustment for potential confounders. The use of ACT was different between the registries (range 40.5–70.0%), even after adjustment for potential confounders. Ninety-day mortality was also different between the registries (range 0.9–13.6%). In multivariable analyses for overall survival, differences were observed between the national and regional registries. Furthermore, patients in ascending age groups and patients with stage II showed a significant worse overall survival.

Conclusions

This study provides a clear insight in clinical practice in the EURECCA Pancreas consortium. The differences observed in (neo-)ACT and outcome give us the chance to further investigate the best practices and improve outcome of pancreatic adenocarcinoma.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Chirurgie

Kombi-Abonnement

Mit e.Med Chirurgie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Chirurgie, den Premium-Inhalten der chirurgischen Fachzeitschriften, inklusive einer gedruckten chirurgischen Zeitschrift Ihrer Wahl.

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Jetzt e.Med zum Sonderpreis bestellen!

Zusatzmaterial
Supplementary material 1 (DOCX 17 kb)
10434_2018_6705_MOESM1_ESM.docx
Supplementary material 2 (DOCX 19 kb)
10434_2018_6705_MOESM2_ESM.docx
Supplementary Fig. S1 Flow chart of inclusion of patients per registry. aIncluded: C25.0-C25.9; excluded: C25.4.15 bIncludes only oncological resections. cUnable to confirm whether patients underwent tumor resection and therefore only used in patient and tumor characteristics description in Table S2 (Supplementary).d Included: 8140-8380, 8500-8585; excluded: 8150-8158, 8240-8249 15 (DOCX 331 kb)
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 12/2018

Annals of Surgical Oncology 12/2018 Zur Ausgabe


 

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise